FDA reinforces GI bleeding risk communication for all OTC NSAID labels
FDA issued updated guidance requiring enhanced gastrointestinal bleeding risk warnings on all OTC NSAID labels, including ibuprofen and naproxen. The update follows a systematic review of FAERS reports and epidemiological data showing underappreciation of GI risk in consumers using NSAIDs for pain relief at labelled doses.
FDA issued updated guidance on 5 September 2026 requiring enhanced gastrointestinal bleeding risk warnings on all OTC NSAID labelling — including ibuprofen (PubChem CID 3672) ↗, naproxen, and aspirin-class OTC products. The key addition is a clearer consumer-facing warning that GI bleeding can occur without warning symptoms and at labelled OTC doses, not just at high doses or with prolonged use. Updated labelling is published on DailyMed ↗.
Background: NSAIDs and GI risk
Non-selective NSAIDs inhibit both COX-1 and COX-2. COX-1 inhibition reduces prostaglandin-mediated protection of the gastric mucosa, increasing susceptibility to ulceration and bleeding. The risk is dose-dependent and additive with other GI risk factors: age >65, history of peptic ulcer disease, concurrent corticosteroids, anticoagulants, or SSRIs. Epidemiological data from NCBI meta-analyses ↗ estimate an approximately 3–5× increase in upper GI bleeding with NSAID use vs non-use. Ibuprofen's GI risk profile compared to other NSAIDs is reviewed in this NCBI comparative review ↗.
FAERS data and regulatory basis
The update was triggered by a systematic review of reports in the FDA Adverse Event Reporting System (FAERS) ↗ and published pharmacoepidemiology studies. FDA noted that consumer surveys suggested underappreciation of GI bleeding risk, particularly among elderly users taking OTC ibuprofen for osteoarthritis pain. The ASHP ↗ and pharmacist bodies were notified to reinforce counselling at point of dispensing.
Risk reduction strategies
To reduce GI risk with NSAIDs: use the lowest effective dose for the shortest duration; take with food; consider co-prescribing a proton pump inhibitor (NCBI) ↗ for high-risk patients; consider selective COX-2 inhibitors (celecoxib) where indicated. Patients on anticoagulants (warfarin, DOACs) should avoid NSAIDs where possible. Full ibuprofen PK data and dose comparison are on the DrugTheGuide ibuprofen page.
FAQ
Does a Boxed Warning mean a drug is being withdrawn?
No. A Boxed Warning ↗ (also called a Black Box Warning) is the FDA's strongest label caution, but the drug remains on the market. It means the agency has determined that a risk is serious enough to require prominent, standardised labelling. The drug continues to be prescribed under appropriate clinical conditions. See the FDA's patient guide to Boxed Warnings ↗.
Where can I read the full updated label?
All current FDA-approved prescribing information is available on DailyMed ↗, maintained by the National Library of Medicine (NLM). Search by drug name to find the most recent label version. Historical label versions are also archived there.